Investor profile
Columbus Venture Partners
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Columbus Venture Partners drives life-changing biotechnology that transforms lives and generates solid returns, investing in therapeutic and industrial products through life science funds. Founded in 2016 by Damià Tormo and Javier García Cogorro, the firm focuses on hard-to-treat, rare, or incurable diseases such as cancer, combining seed-stage therapeutic funding with infrastructure creation to build complete value chains. Its funds are split 50% between advanced therapies and industrial/biotech infrastructure development, with exit strategies designed before investing to maximize capital and shorten return timelines. With over €400M under management across four funds, Columbus has backed ~50 biotech companies spanning Spain, the US, and the UK, achieving notable exits including the €4B Bayer acquisition of Viralgen and the €205M sale of Sanifit to Vifor Pharma.
Notable quotes
“We are excited about the exclusive viral vector capabilities this partnership will create. Viralgen success will be based on three areas: outstanding technology, quality of the location to attract talent, and commitment from the Basque Country Government.”
“At Columbus, we look for companies that combine world-class science with a clear path to clinical impact. Ona is a strong example of that. Its work on cancer resistance and metastasis addresses one of the most important challenges in oncology, and its pipeline, led by ONA-255 and followed by ONA-389, provides a compelling opportunity to build a differentiated oncology platform.”
“No other investment fund combines therapeutic seed funding with infrastructure creation, building complete value chains and shortening return timelines.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Ona Therapeutics | Series B | $87m | 2026-06-04 |
| Visium | Seed | — | 2025-01-01 |
| Tolerance Bio | Seed | $17m | 2024-10-15 |
| ARTHEx Biotech | Series A | $46m | 2023-01-01 |
| Highlight Therapeutics | Series A | $23m | 2021-01-01 |
| Viralgen | Seed | — | 2017-10-17 |
| Sanifit Therapeutics | Series D | $81m | 2019-06-26 |
| Aura Biosciences | Series B+ | — | 2018-01-01 |
| Minoryx Therapeutics | Series B+ | — | 2019-01-01 |
| Aleta Biotherapeutics | Series A | — | 2024-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| CDTI / Innvierte | 5 |
| Alta Life Sciences | 4 |
| Ysios Capital | 3 |
| Mérieux Equity Partners | 2 |
| Caixa Capital Risc | 2 |
| Asabys Partners | 2 |
Fit check
Is Columbus Venture Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit